Development of lentiviral vectors for antiangiogenic gene delivery

Toshiaki Shichinohe, Bernard H. Bochner, Kazuo Mizutani, Miyako Nishida, Susan Hegerich-Gilliam, Luigi Naldini, Noriyuki Kasahara

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Growth and metastasis of malignant tumors requires angiogenesis. Inhibition of tumor-induced angiogenesis may represent an effective cytostatic strategy. We have constructed recombinant self-inactivating lentiviral vectors expressing angiostatin and endostatin, and have tested their antiangiogenic activities. As VSV-G-pseudotyped lentiviral vectors showed low relative transduction titers on bovine aortic and human umbilical vein endothelial cells, it was difficult to achieve significant inhibition of endothelial cell growth by lentivirus-mediated antiangiogenic gene transfer directly to endothelial cells without concomitant vector-associated cytotoxicity. However, lentivirus vectors could efficiently and stably transduce T24 human bladder cancer cells that are relatively resistant to adenovirus infection due to loss of coxsackievirus-adenovirus receptor expression. Long-term expression and secretion of angiostatin and endostatin from lentivirus-transduced T24 cells resulted in significant inhibition of cellular proliferation on coculture with endothelial cells. This report represents the first use of lentivirus-based vectors to deliver the antiangiogenic factors, angiostatin and endostatin, and suggests the potential utility of antiangiogenic gene therapy with lentiviral vectors for the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)879-889
Number of pages11
JournalCancer Gene Therapy
Volume8
Issue number11
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Lentivirus
Angiostatins
Endostatins
Endothelial Cells
Genes
Adenoviridae Infections
Neoplasms
Enterovirus
Human Umbilical Vein Endothelial Cells
Cytostatic Agents
Growth
Coculture Techniques
Urinary Bladder Neoplasms
Genetic Therapy
Cell Proliferation
Neoplasm Metastasis
Therapeutics

Keywords

  • Angiostatin
  • Endostatin
  • Lentivirus
  • Vector

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Shichinohe, T., Bochner, B. H., Mizutani, K., Nishida, M., Hegerich-Gilliam, S., Naldini, L., & Kasahara, N. (2001). Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Therapy, 8(11), 879-889. https://doi.org/10.1038/sj.cgt.7700388

Development of lentiviral vectors for antiangiogenic gene delivery. / Shichinohe, Toshiaki; Bochner, Bernard H.; Mizutani, Kazuo; Nishida, Miyako; Hegerich-Gilliam, Susan; Naldini, Luigi; Kasahara, Noriyuki.

In: Cancer Gene Therapy, Vol. 8, No. 11, 2001, p. 879-889.

Research output: Contribution to journalArticle

Shichinohe, T, Bochner, BH, Mizutani, K, Nishida, M, Hegerich-Gilliam, S, Naldini, L & Kasahara, N 2001, 'Development of lentiviral vectors for antiangiogenic gene delivery', Cancer Gene Therapy, vol. 8, no. 11, pp. 879-889. https://doi.org/10.1038/sj.cgt.7700388
Shichinohe T, Bochner BH, Mizutani K, Nishida M, Hegerich-Gilliam S, Naldini L et al. Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Therapy. 2001;8(11):879-889. https://doi.org/10.1038/sj.cgt.7700388
Shichinohe, Toshiaki ; Bochner, Bernard H. ; Mizutani, Kazuo ; Nishida, Miyako ; Hegerich-Gilliam, Susan ; Naldini, Luigi ; Kasahara, Noriyuki. / Development of lentiviral vectors for antiangiogenic gene delivery. In: Cancer Gene Therapy. 2001 ; Vol. 8, No. 11. pp. 879-889.
@article{674a97c9c6ee4358bb17e1b89ca03ef2,
title = "Development of lentiviral vectors for antiangiogenic gene delivery",
abstract = "Growth and metastasis of malignant tumors requires angiogenesis. Inhibition of tumor-induced angiogenesis may represent an effective cytostatic strategy. We have constructed recombinant self-inactivating lentiviral vectors expressing angiostatin and endostatin, and have tested their antiangiogenic activities. As VSV-G-pseudotyped lentiviral vectors showed low relative transduction titers on bovine aortic and human umbilical vein endothelial cells, it was difficult to achieve significant inhibition of endothelial cell growth by lentivirus-mediated antiangiogenic gene transfer directly to endothelial cells without concomitant vector-associated cytotoxicity. However, lentivirus vectors could efficiently and stably transduce T24 human bladder cancer cells that are relatively resistant to adenovirus infection due to loss of coxsackievirus-adenovirus receptor expression. Long-term expression and secretion of angiostatin and endostatin from lentivirus-transduced T24 cells resulted in significant inhibition of cellular proliferation on coculture with endothelial cells. This report represents the first use of lentivirus-based vectors to deliver the antiangiogenic factors, angiostatin and endostatin, and suggests the potential utility of antiangiogenic gene therapy with lentiviral vectors for the treatment of cancer.",
keywords = "Angiostatin, Endostatin, Lentivirus, Vector",
author = "Toshiaki Shichinohe and Bochner, {Bernard H.} and Kazuo Mizutani and Miyako Nishida and Susan Hegerich-Gilliam and Luigi Naldini and Noriyuki Kasahara",
year = "2001",
doi = "10.1038/sj.cgt.7700388",
language = "English (US)",
volume = "8",
pages = "879--889",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Development of lentiviral vectors for antiangiogenic gene delivery

AU - Shichinohe, Toshiaki

AU - Bochner, Bernard H.

AU - Mizutani, Kazuo

AU - Nishida, Miyako

AU - Hegerich-Gilliam, Susan

AU - Naldini, Luigi

AU - Kasahara, Noriyuki

PY - 2001

Y1 - 2001

N2 - Growth and metastasis of malignant tumors requires angiogenesis. Inhibition of tumor-induced angiogenesis may represent an effective cytostatic strategy. We have constructed recombinant self-inactivating lentiviral vectors expressing angiostatin and endostatin, and have tested their antiangiogenic activities. As VSV-G-pseudotyped lentiviral vectors showed low relative transduction titers on bovine aortic and human umbilical vein endothelial cells, it was difficult to achieve significant inhibition of endothelial cell growth by lentivirus-mediated antiangiogenic gene transfer directly to endothelial cells without concomitant vector-associated cytotoxicity. However, lentivirus vectors could efficiently and stably transduce T24 human bladder cancer cells that are relatively resistant to adenovirus infection due to loss of coxsackievirus-adenovirus receptor expression. Long-term expression and secretion of angiostatin and endostatin from lentivirus-transduced T24 cells resulted in significant inhibition of cellular proliferation on coculture with endothelial cells. This report represents the first use of lentivirus-based vectors to deliver the antiangiogenic factors, angiostatin and endostatin, and suggests the potential utility of antiangiogenic gene therapy with lentiviral vectors for the treatment of cancer.

AB - Growth and metastasis of malignant tumors requires angiogenesis. Inhibition of tumor-induced angiogenesis may represent an effective cytostatic strategy. We have constructed recombinant self-inactivating lentiviral vectors expressing angiostatin and endostatin, and have tested their antiangiogenic activities. As VSV-G-pseudotyped lentiviral vectors showed low relative transduction titers on bovine aortic and human umbilical vein endothelial cells, it was difficult to achieve significant inhibition of endothelial cell growth by lentivirus-mediated antiangiogenic gene transfer directly to endothelial cells without concomitant vector-associated cytotoxicity. However, lentivirus vectors could efficiently and stably transduce T24 human bladder cancer cells that are relatively resistant to adenovirus infection due to loss of coxsackievirus-adenovirus receptor expression. Long-term expression and secretion of angiostatin and endostatin from lentivirus-transduced T24 cells resulted in significant inhibition of cellular proliferation on coculture with endothelial cells. This report represents the first use of lentivirus-based vectors to deliver the antiangiogenic factors, angiostatin and endostatin, and suggests the potential utility of antiangiogenic gene therapy with lentiviral vectors for the treatment of cancer.

KW - Angiostatin

KW - Endostatin

KW - Lentivirus

KW - Vector

UR - http://www.scopus.com/inward/record.url?scp=0035190393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035190393&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700388

DO - 10.1038/sj.cgt.7700388

M3 - Article

VL - 8

SP - 879

EP - 889

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 11

ER -